Vanda Submits Application for New GPP Treatment
Vanda Pharmaceuticals files FDA application for imsidolimab, a promising new treatment for generalized pustular psoriasis, with potential approval by mid-2026.
/ 10 items
#VNDA↓
FDA Clears Vanda's Tradipitant for Motion Sickness Studies
The FDA has lifted a study restriction on Vanda Pharmaceuticals' Tradipitant, potentially making it the first new motion sickness drug in decades.
Vanda's Motion Sickness Drug Faces More Delays
Vanda Pharmaceuticals' (VNDA) tradipitant approval delayed again as FDA extends clinical hold review while labeling issues emerge for the motion sickness treatment.
Pharma Stock Moves: Oppenheimer Downgrades Rhythm, New Buys on Vanda, Verrica, CervoMed, and Ventyx
Oppenheimer downgrades Rhythm Pharmaceuticals after major gains, while analysts issue fresh Buy ratings on Vanda, Verrica, CervoMed, and Ventyx highlighting key catalysts and growth potential.